focus -WSS

focus

author：comprehensive 2025-09-29 01:36:23 - browse：56

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Carbon Health diabetes program, a test of data

entertainment

hotspot

WSS

Abbott's new heart device gets FDA advisory panel nod

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress considering partial increase for doctor pay in Medicare

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Resistance to opioid

UnitedHealth sued over use of algorithm in Medicare Advantage plans

focus

focus

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Type 2 diabetes prevention programs work at large scale: study

Medical records are filled with copy

Congress might make insulin pumps more accessible to the blind

Dobbs anniversary: the lost opportunity of abortion as health care

Ventyx halts psoriasis drug development after lackluster trial results

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Supreme Court strikes down use of affirmative action

Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

White House drug czar issues call for 'recovery

Congress must protect the remaining independent doctors

How state and local governments are sidelining science

White House drug czar issues call for 'recovery

White House drug czar issues call for 'recovery

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

entertainment

hotspot

hotspot

entertainment